Novo Nordisk announced on Friday morning that its CEO Lars Fruergaard Jørgensen is stepping down after leading the company for eight years. In a release announcing the decision, the Danish pharma ...

If you’ve been on TikTok or any other social media — or any kind of media, for that matter — you’ve probably come across ...

Novo Nordisk CEO Lars Jørgensen to step down amid increasing pressure from obesity drug competition and recent share price ...

GLP-1 drugs like Wegovy and Ozempic are designed to treat type 2 diabetes, but are widely known for their effect on weight ...

The trial aims to enroll 40 patients with FGFR alterations across the US, who won't need to travel far to receive care.

As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...

For everything that was wrong about WeightWatchers, once upon a time it did something right. It tapped into the power of ...

Frier Levitt will host a May 15 webinar on legal risks, compounding regulations and market trends impacting GLP-1 prescribers ...

U.S.-based EHR giants such as Epic, Oracle Health, Meditech and Altera are facing mounting competition from a new generation of regional and international vendors, according to a May 10 report from ...

Some of the bankrupt company’s closest rivals, newer telehealth firms, face a new challenge of their own as federal ...

A Comprehensive Review of MEDVi’s Personalized GLP-1 Weight Loss Solutions Featuring Affordable Compounded Semaglutide and ...

Hims & Hers stock has surged due to impressive quarterly results, rapid weight-loss product expansion, and a strategic Novo ...